Difference between revisions of "Napsin A"
Jump to navigation
Jump to search
| Line 13: | Line 13: | ||
*[[Colorectal adenocarcinoma]].<ref name=pmid19740516/> | *[[Colorectal adenocarcinoma]].<ref name=pmid19740516/> | ||
*[[Pancreatic adenocarcinoma]].<ref name=pmid19740516/> | *[[Pancreatic adenocarcinoma]].<ref name=pmid19740516/> | ||
*[[Breast carcinoma]] | *[[Breast carcinoma]] (0 positive of 17 cases<ref name=pmid19740516/>). | ||
==See also== | ==See also== | ||
Revision as of 14:02, 5 October 2015
Napsin A, also Napsin, is a commonly used immunostain in pulmonary pathology.
Positive
- Lung adenocarcinoma - 83% of cases.[1]
- Papillary renal cell carcinoma 79% of cases.[1]
Occasionally positive
- Clear cell renal cell carcinoma - 34% of cases.[1]
- Papillary thyroid carcinoma - 2/81 cases, tall cell variant only.[1]
Negative
- Squamous cell carcinoma of the lung.[1]
- Colorectal adenocarcinoma.[1]
- Pancreatic adenocarcinoma.[1]
- Breast carcinoma (0 positive of 17 cases[1]).
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Bishop, JA.; Sharma, R.; Illei, PB. (Jan 2010). "Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.". Hum Pathol 41 (1): 20-5. doi:10.1016/j.humpath.2009.06.014. PMID 19740516.